Evotec SE (EVO)
| Bid | 2.61 |
| Market Cap | 1.29B |
| Revenue (ttm) | 1.56B |
| Net Income (ttm) | -343.06M |
| EPS (ttm) | -0.53 |
| PE Ratio (ttm) | -6.83 |
| Forward PE | -10 |
| Analyst | Hold |
| Ask | 4.54 |
| Volume | 65,815 |
| Avg. Volume (20D) | 81,400 |
| Open | 3.53 |
| Previous Close | 3.51 |
| Day's Range | 3.52 - 3.63 |
| 52-Week Range | 2.85 - 7.98 |
| Beta | 0.96 |
About EVO
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly;...
Analyst Forecast
According to 2 analyst ratings, the average rating for EVO stock is "Hold." The 12-month stock price forecast is $5.9, which is an increase of 62.98% from the latest price.
Stock Forecasts
3 weeks ago · accessnewswire.com
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers SquibbOngoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / E...
